1. Unquantifiably low aldosterone concentrations are prevalent in hospitalised COVID-19 patients but may not be revealed by chemiluminescent immunoassay
- Author
-
Martin Wiegand, David J Halsall, Sarah L Cowan, Kevin Taylor, Robert J B Goudie, Jacobus Preller, and Mark Gurnell
- Subjects
covid-19 ,sars-cov-2 ,renin-angiotensinaldosterone system ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Objective: Previous studies have reported conflicting findings regarding al dosterone levels in patients hospitalised with COVID-19. We therefore used the gold-standard technique of liquid chromatography–tandem mass spectrometry (LCMSMS) to address this uncertainty. Design: All patients admitted to Cambridge University Hospitals with COVID-19 between 10 March 2020 and 13 May 2021, and in whom a stored blood sample was available for analysis, were eligible for inclusion. Methods: Aldosterone was measured by LCMSMS and by immunoassay; cortisol and renin were determined by immunoassay. Results: Using LCMSMS, aldosterone was below the limit of detection ( 744 nmol/L (P = 0.005). Conclusion: When measured by LCMSMS, aldosterone was found to be profoundly low in a significant proportion of patients with COVID-19 at the time of hospital admission. This has likely not been detected previously due to high levels of interference with immunoassays in patients with COVID-19, and this merits further prospective investigation.
- Published
- 2022
- Full Text
- View/download PDF